{
    "ticker": "YMAB",
    "name": "Yumanity Therapeutics, Inc.",
    "description": "Yumanity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases. Founded in 2014 and based in Cambridge, Massachusetts, Yumanity harnesses its proprietary drug discovery platform to identify and advance novel drug candidates aimed at treating conditions such as Alzheimer\u2019s disease, Parkinson\u2019s disease, and other related disorders. The company utilizes a unique approach that combines artificial intelligence, neurobiology, and medicinal chemistry to discover compounds that can restore cellular health and function in diseased neurons. Yumanity's lead product candidate, YTX-7739, is an orally administered small molecule that has shown promise in preclinical studies and is currently undergoing clinical trials. With a mission to transform the treatment landscape for neurodegenerative diseases, Yumanity is committed to addressing significant unmet medical needs through its innovative pipeline and collaborative research efforts. The company aims to provide new hope for patients suffering from debilitating neurological disorders, emphasizing a deep understanding of disease mechanisms and potential therapeutic interventions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.yumanity.com",
    "ceo": "Richard L. P. L. Tsai",
    "social_media": {
        "twitter": "https://twitter.com/YumanityT",
        "linkedin": "https://www.linkedin.com/company/yumanity-therapeutics"
    },
    "investor_relations": "https://ir.yumanity.com",
    "key_executives": [
        {
            "name": "Richard L. P. L. Tsai",
            "position": "CEO"
        },
        {
            "name": "Christine L. Carr",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "YTX-7739"
            ]
        }
    ],
    "seo": {
        "meta_title": "Yumanity Therapeutics, Inc. | Innovative Therapies for Neurodegenerative Diseases",
        "meta_description": "Explore Yumanity Therapeutics, Inc., a biotechnology company focused on developing novel therapies for neurodegenerative diseases like Alzheimer\u2019s and Parkinson\u2019s. Learn about our innovative drug discovery platform and pipeline.",
        "keywords": [
            "Yumanity Therapeutics",
            "Neurodegenerative Diseases",
            "Biotechnology",
            "Alzheimer's Disease",
            "Parkinson's Disease",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Yumanity Therapeutics focus on?",
            "answer": "Yumanity Therapeutics focuses on developing innovative therapies for neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of Yumanity Therapeutics?",
            "answer": "Richard L. P. L. Tsai is the CEO of Yumanity Therapeutics, Inc."
        },
        {
            "question": "Where is Yumanity headquartered?",
            "answer": "Yumanity is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Yumanity's lead product candidate?",
            "answer": "Yumanity's lead product candidate is YTX-7739."
        },
        {
            "question": "When was Yumanity founded?",
            "answer": "Yumanity was founded in 2014."
        }
    ],
    "competitors": [
        "BIIB",
        "ADMS",
        "AVXL"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}